Biotech News
Delcath Systems Reports Third Quarter 2026 Results and Business Highlights
Increases 2026 Revenue Guidance to a Range of $115 million to $117 million Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, N.Y. --(BUSINESS WIRE)--Nov. 9, 2026-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic
